| Title |
Amyotrophic Lateral Sclerosis Associated with Statin Use: A Disproportionality Analysis of the FDA’s Adverse Event Reporting System
|
|---|---|
| Published in |
Drug Safety, February 2018
|
| DOI | 10.1007/s40264-017-0620-4 |
| Pubmed ID | |
| Authors |
Beatrice A. Golomb, Abril Verden, Alexis K. Messner, Hayley J. Koslik, Keith B. Hoffman |
| Abstract |
Apparent elevations in reporting of amyotrophic lateral sclerosis (ALS)-like conditions associated with statin use have been previously described from data obtained via US and European databases. The aim of this study was to examine US FDA Adverse Event Reporting System (FAERS) data to compare reporting odds ratios (RORs) of ALS and ALS-like conditions between statins and other drugs, for each statin agent. We assessed for disproportional rates of reported ALS and ALS-related conditions for each statin agent separately by using the ROR formula. FAERS data were analyzed through September 2015. RORs for ALS were elevated for all statins, with elevations possibly stronger for lipophilic statins. RORs ranged from 9.09 (6.57-12.6) and 16.2 (9.56-27.5) for rosuvastatin and pravastatin (hydrophilic) to 17.0 (14.1-20.4), 23.0 (18.3-29.1), and 107 (68.5-167) for atorvastatin, simvastatin, and lovastatin (lipophilic), respectively. For simvastatin, an ROR of 57.1 (39.5-82.7) was separately present for motor neuron disease. These findings extend previous evidence showing that significantly elevated ALS reporting extends to individual statin agents, and add to concerns about potential elevated occurrence of ALS-like conditions in association with statin usage. |
X Demographics
The data shown below were collected from the profiles of 684 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 160 | 23% |
| United Kingdom | 38 | 6% |
| Canada | 30 | 4% |
| Australia | 13 | 2% |
| Netherlands | 7 | 1% |
| France | 6 | <1% |
| New Zealand | 5 | <1% |
| South Africa | 5 | <1% |
| Spain | 5 | <1% |
| Other | 43 | 6% |
| Unknown | 372 | 54% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 565 | 83% |
| Practitioners (doctors, other healthcare professionals) | 83 | 12% |
| Scientists | 29 | 4% |
| Science communicators (journalists, bloggers, editors) | 7 | 1% |
Mendeley readers
The data shown below were compiled from readership statistics for 48 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 48 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 10 | 21% |
| Researcher | 8 | 17% |
| Student > Master | 6 | 13% |
| Student > Postgraduate | 3 | 6% |
| Student > Ph. D. Student | 3 | 6% |
| Other | 6 | 13% |
| Unknown | 12 | 25% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 10 | 21% |
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 13% |
| Neuroscience | 5 | 10% |
| Biochemistry, Genetics and Molecular Biology | 4 | 8% |
| Agricultural and Biological Sciences | 3 | 6% |
| Other | 6 | 13% |
| Unknown | 14 | 29% |
Attention Score in Context
This research output has an Altmetric Attention Score of 479. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 April 2024.
All research outputs
#56,812
of 25,793,330 outputs
Outputs from Drug Safety
#5
of 1,873 outputs
Outputs of similar age
#1,401
of 454,300 outputs
Outputs of similar age from Drug Safety
#1
of 29 outputs
Altmetric has tracked 25,793,330 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,873 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.6. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 454,300 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 29 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 96% of its contemporaries.